Molecular phenotype of the foci in multifocal invasive breast carcinomas: Intertumoral heterogeneity is related to shorter survival and may influence the choice of therapy

Cancer

Volumn 120, Issue 1, 2014, Pages 26-34

  Pekar, Gyula ^a   Gere, Maria ^a   Tarjan, Miklos ^a   Hellberg, Dan ^b   Tot, Tibor ^a  

^a FALUN HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

histologic grade; histologic type; intertumoral heterogeneity; molecular phenotypes; multifocal breast cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER MORTALITY; CANCER PROGNOSIS; DISEASE SPECIFIC SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; MULTIFOCAL INVASIVE BREAST CARCINOMA; MULTIPLE CANCER; PHENOTYPIC VARIATION; PRIORITY JOURNAL; TISSUE MICROARRAY; TRIPLE NEGATIVE BREAST CANCER; TUMOR VOLUME;

HISTOLOGIC GRADE; HISTOLOGIC TYPE; INTERTUMORAL HETEROGENEITY; MOLECULAR PHENOTYPES; MULTIFOCAL BREAST CANCER;

BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; PHENOTYPE; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TISSUE ARRAY ANALYSIS;

EID: 84890786511     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28375     Document Type: Article

References (41)

1. Elston CW, Ellis IO,. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991; 19: 403-410.
2. Elston CW, Ellis IO,. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up [C.W. Elston & I.O. Ellis. Histopathology 1991;19:403-410]. Histopathology. 2002; 41: 151-153 (Pubitemid 41713015)
3. Galea MH, Blamey RW, Elston CE, et al. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat. 1992; 22: 207-219.
4. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumors. Nature. 2000; 406: 747-752.
5. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001; 98: 10869-10874. (Pubitemid 32878711)
6. Weigelt B, Baehner FL, Reis-Filho JS,. The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. J Pathol. 2009; 220: 263-280.
7. Foulkes WD, Smith IE, Reis-Filho JR,. Triple-negative breast cancer. N Engl J Med. 2010; 363: 1938-1948.
8. Aebi S, Sun Z, Braun D, et al. Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: long-term follow up on IBCSG Trial IX. Ann Oncol. 2011; 22: 1981-1987.
9. Wo JY, Taghian AG, Nguyen PL, et al. The association between biological subtype and isolated regional nodal failure after breast-conserving therapy. Int J Radiat Oncol Biol Phys. 2010; 77: 188-196.
10. Ogino S, Fuchs CS, Giovannucci E,. How many molecular subtypes? Implications of the unique tumor principle in personalized medicine. Expert Rev Mol Diagn. 2012; 12: 621-628.
11. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004; 10: 5367-5374. (Pubitemid 39100473)
12. Dolled-Filhart M, Ryden L, Cregger M, et al. Classification of breast cancer using genetic algorithms and tissue microarrays. Clin Cancer Res. 2006; 12: 6459-6468. (Pubitemid 44799719)
13. Blows FM, Driver KE, Schimdt MK, et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and term survival: a collaborative analysis of data for 10,159 cases from 12 studies [serial online]. PLoS Med. 2010; 7: e1000279.
14. Westman-Naeser S, Bengtsson E, Eriksson O, et al. Multifocal breast carcinoma. Am J Surg. 1981; 142: 255-257. (Pubitemid 11034271)
15. Egan RL,. Multicentric breast carcinomas: clinical-radiographic- pathologic whole organ studies and 10-year survival. Cancer. 1982; 49: 1123-1130. (Pubitemid 12187811)
16. Holland R, Veiling SH, Mravunac M, et al. Histologic multifocality of Tis, T1-2 breast carcinomas. Implications for clinical trials of breast conserving surgery. Cancer. 1985; 56: 979-990. (Pubitemid 15003474)
17. Tot T,. Axillary lymph node status in unifocal, multifocal, and diffuse breast carcinomas: differences are related to macrometastatic disease. Ann Surg Oncol. 2012; 19: 3395-3401.
18. Weissenbacher TM, Zschage M, Janni W, et al. Multicentric and multifocal versus unifocal breast cancer: is the tumor-node-metastasis classification justified? Breast Cancer Res Treat. 2010; 122: 27-34.
19. Boyages J, Jayasinghe UW, Coombs N,. Multifocal breast cancer and survival: each focus does matter particularly for larger tumours. Eur J Cancer. 2010; 46: 1990-1996.
20. Bendifallah S, Werkoff G, Borie-Moutafoff C, et al. Multiple synchronous (multifocal and multicentric) breast cancer: clinical implications. Surg Oncol. 2010; 19: e115-e123.
21. Tot T, Gere M, Pekar Gy, et al. Breast cancer multifocality, disease extent, and survival. Hum Pathol. 2011; 42: 1761-1769.
22. Garimella V, Long ED, O'Kane SL, et al. Oestrogen and progesterone status of individual foci in multifocal invasive ductal cancer. Acta Oncol. 2007; 46: 204-207.
23. Buggi F, Folli S, Curcio A, et al. Multicentric/multifocal breast cancer with a single histotype: is the biological characterization of all individual foci justified? Ann Oncol. 2012; 23: 2042-2046.
24. Choi Y, Kim EJ, Seol H, et al. The hormone receptor, human epidermal growth factor receptor 2, and molecular subtype status of individual tumor foci in multifocal/multicentric invasive ductal carcinoma of breast. Hum Pathol. 2012; 43: 48-55.
25. Tot T,. The clinical relevance of the distribution of the lesions in 500 consecutive breast cancer cases documented in large-format histological sections. Cancer. 2007; 7: 581-587.
26. Tavassoli FA, Devilee P, eds. World Health Organization Classification of Tumours: Pathology and Genetics. Tumours of the Breast and Female Genital Organs. Lyon, France: IARC Press; 2003.
27. Tot T,. Early and more advanced unifocal and multifocal breast carcinomas and their molecular phenotypes. Clin Breast Cancer. 2011; 11: 258-263.
28. Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011; 22: 1736-1747.
29. Sotiriou C, Wiraparti P, Loi S, Harris A, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst. 2006; 98: 262-272 (Pubitemid 43264710)
30. Sotiriou C, Pusztai L,. Gene-expression signatures in breast cancer. N Engl J Med. 2009; 360: 790-800.
31. Lester SC, Bose S, Chen YY, et al. Members of the Cancer Committee, College of American Pathologists. Protocol for the examination of specimens from patients with invasive carcinoma of the breast. Arch Pathol Lab Med. 2009; 133: 1515-1538.
32. Tot T, Tabar L, Dean PB,. Practical Breast Pathology. Stuttgart, Germany: Thieme; 2002.
33. Boros M, Marian C, Moldovan C, Stolnicu S,. Morphological heterogeneity of the simultaneous ipsilateral invasive tumor foci in breast carcinoma: a retrospective study of 418 cases of carcinomas. Pathol Res Pract. 2012; 208: 604-609.
34. Gallager HS, Martin JE,. The study of mammary carcinoma by mammography and whole organ sectioning. Early observations. Cancer. 1969; 23: 855-873.
35. Tot T,. Subgross morphology, the sick lobe hypothesis, and the success of breast conservation [serial online]. Int J Breast Cancer. 2011; 2011: 634021.
36. Tucker FL,. Imaging-assisted large-format breast pathology: program rationale and development in a nonprofit health system in the United States [serial online]. Int J Breast Cancer. 2012; 2012: 171792.
37. Tot T, Pekar G,. Multifocality in "basal-like" breast carcinomas and its influence on lymph node status. Ann Surg Oncol. 2011; 18: 1671-1677.
38. Tot T,. The role of large-format histopathology in assessing subgross morphological prognostic parameters: a single institution report of 1000 consecutive breast cancer cases [serial online]. Int J Breast Cancer. 2012; 2012: 395415.
39. Joergensen LE, Gunnarsdottir KA, Lanng C, et al. Multifocality as a prognostic factor in breast cancer patients registered in Danish Breast Cancer Cooperative Group (DBCG) 1996-2001. Breast. 2008; 17: 587-591.
40. Pekar G, Hofmeyer S, Tabar L, et al. Multifocal breast cancer documented in large-format histology sections: long-term follow-up results by molecular phenotypes. Cancer. 2013; 119: 1132-1139.
41. Desmedt C, Nik-Zainal S, Fumagalli D, et al. Characterization of different foci of multifocal breast cancer using genomic, transcriptomic and epigenomic data [abstract]. Abstracts: Thirty-Fifth Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 4-8, 2012; San Antonio, TX. Cancer Res. 2012;72(24 suppl). Abstract nr S60-2.